TR Pro+® is supported by a comprehensive body of scientific and clinical research which sets it apart it from other aftercare products that heal skin. The information that underpins TR Pro+® and its active ingredient, Glucoprime®, has enabled inclusion on the Australian Register of Therapeutic Goods (ARTG). This signifies Tissue Repairs commitment to adhering to stringent regulatory requirements, and to meeting the highest standards in relation to product safety, efficacy and quality. TR Pro+® is manufactured in a GMP accredited facility that complies with internationally recogised standards for medicines manufacture.
Pre-clinical Studies
Ridder, W.E.Study Number 500663 (2008)
In a Goettingen mini-pig model, histological examination of comparisons between TR Pro+® gel and placebo demonstrated that the most marked increase in epidermal thickness occurred at the TR Pro+® test sites after daily administration for 5 days. Microscopically, the primary effects of the TR Pro+® therapy were enhanced migration of macrophages and neutrophils into the wound space, followed by earlier onset of all aspects of the healing cascade. Histological examination of the punch biopsy samples showed significant cellular changes with regenerative processes commencing sooner at sites where the active treatment had been applied, based on changes in the stratum lucidum and stratum corneum.
Roy S, et al. Particulate beta–glucan induces TNF-α production in wound macrophages via a redox-sensitive NF-κβ-dependent pathway. Wound Repair Regen. 2011 May-Jun;19(3):411-9.
In this study, the hypothesis that TR Pro+® regulates wound macrophage function was tested. TR Pro+® induced tumor necrosis factor (TNF) α transcription in macrophages isolated from murine wound sites. Multiplex assay identified interleukin (IL)-10 and TNFα as two cytokines that are induced by TR Pro+® in human blood monocyte-derived macrophages. TR Pro+® -induced TNFα production was observed to be mediated via the TLR-2 and dectin-1 receptors, receptor tyrosine kinases and NFκB activation. Consistently, TR Pro+® induced TNFα expression in wound-site macrophages isolated from two patients with chronic wounds. These observations establish the translational significance of the net findings of this study. Activation of wound macrophages by TR Pro+® represents one of the potential mechanisms by which this beta-glucan may benefit chronic wounds where inefficient inflammatory response is one of the underlying causes of impaired healing.
Mills, S, et al. Beta-Glucan Hydrogel (TR Pro+®) modulates inflammation, by controlling macrophage differentiation, to improve the rate of healing in murine excisional wounds. AWTRS Abstract October 2024.
C57BL/6 mice received 10mm circular wounds to their dorsum, which were treated at the time of wounding, with TR Pro+® hydrogel or hydrogel alone. Three time points were investigated including day 3, day 7 and day 14. At these time points wound measurements, collagen deposition, immune cell infiltrate, growth factor and cytokine expression were investigated.
The data showed that TR Pro+® treatment significantly reduced macroscopic wound gape and microscopic wound area and width at day 7, when compared to hydrogel treatment. The inflammatory profile, at day 7, showed a greater number of macrophages within the TR Pro+® treated wound site but the ratio of M1:M2 macrophages showed a greater proportion of M2 macrophages, when compared to the hydrogel control. This higher ratio of M2 macrophages indicates a resolution of inflammation and a progression in the wound healing process, which is beneficial for healing outcomes.
In summary, TR Pro+® hydrogel treatment increased the rate of wound closure by regulating macrophage differentiation. This modulated the immune response by limiting pro-inflammatory responses yet simultaneously promoting a wound resolving anti-inflammatory phenotype. This area of research is showing that beta-glucan therapy could hold promising therapeutic potential for wound healing
Clinical Studies
Two Phase 2 studies (GLYC-101-1a and GLYC-101-1b) were conducted to test TR Pro+® treatment after retro-auricular CO2 laser skin resurfacing (LSR) and CO2 laser skin resurfacing. Both studies demonstrated an acceptable safety profile when administering TR Pro+® . The studies demonstrated the time to healing was shorter (10.9 days) in the TR Pro+® group than in both the 1.0% Glucoprime® (13.1 days) and placebo (16.3 days) groups; the difference between TR Pro+® and placebo treatment was statistically significant (p=0.0062) (Angra et al. 2021).
Wu DC et al. A Novel Macrophage-Activating Gel Improves Healing and Skin Quality After CO2 Laser Resurfacing of the Chest. Dermatol Surg. 2022 Dec 1;48(12):1312-1316
A third study compared TR Pro+® against a placebo gel on 42 healthy subjects that had undergone fractionated CO2 laser resurfacing to the chest. Treatment occured once daily for 5 days with and assessment of skin quality made at 28 day. The study demonstrated that TR Pro+® treatment reduced redness, cutaneous wrinkling and improved elastosis, using the Fitzpatrick-Goldman Classification. With regard to wrinkling, 85% of responders achieved a ≥ 1-point improvement in scores between baseline and day 28 in the active group compared to only 50% in the placebo group, corresponding to an absolute improvement of 35% (p=0.04). For elastosis there were 75% of responders who achieved a ≥ 3-point improvement in scores between baseline and day 28 in the active group compared to 35% in the placebo group. This represents an absolute improvement of 40% (p=0.011). TR Pro+® can shorten downtime and reduce wrinkling due to an increased rate of physiologic dermal collagen production.
Real-World Evidence Studies
Patient Experiential Program, IQVIA, September 2022
A multi-clinic (n=12) real-world evidence study involving 48 patients who had undergone a range of aesthetic and medical procedures was undertaken to collect patient feedback following aftercare treatment with TR Pro+®. The feedback was collected anonymously via an online portal at days 6 and 28.
Patients overwhelmingly reported a reduction in itchiness and tingling following the application of TR Pro+®, as well as increased hydration. When patients were asked how they perceived their skin to be healing, 85% reported it as well/very well. When patients who had had prior procedures were asked how their healing with TR Pro+® compared to previous occasions, 100% reported that it was as good as, or better than previous.
It is likely that the ability of TR Pro+® to modulate post-procedure inflammation leads to reduced itchiness and tingling. The increased number of M2 macrophages made available by TR Pro+® are able to commence healing earlier and ensure superior skin quality.